First Day of Dealings

Syntopix Group plc
23 March 2006


For immediate release                                              23 March 2006


                             SYNTOPIX GROUP PLC
                         ('Syntopix' or 'the Company')

                FIRST DAY OF DEALINGS ON THE AIM MARKET OF
                        THE LONDON STOCK EXCHANGE


Syntopix Group plc, (AIM: SYN) a drug discovery and development company focused
on dermatological diseases, announces its flotation on the AIM market of the
London Stock Exchange today.


Highlights of the Placing:


•  £4.0 million (£3.3 million net of expenses) has been raised for
   Syntopix via a placing at 177 pence per share



•  On admission the market capitalisation of Syntopix at the placing
   price will be £10.1 million



•  The proceeds of the placing will be used to finance the Company's drug
   development programmes in dermatology



•  KBC Peel Hunt Ltd is the Company's Nominated Adviser and Broker


Business Highlights:


•  Syntopix was formed in 2003 as a spin-out from the University of Leeds
to commercialise the research of the Company's two scientific founders, Dr Jon
Cove and Dr Anne Eady, into antibiotic resistance and diseases of the skin.



•  Syntopix has a growing patent portfolio and a pipeline of nine drug
candidates awaiting preclinical and clinical trials in acne and MRSA.



•  The Company has a highly experienced scientific, commercial and
non-executive team who between them have a proven track record of developing
pharmaceutical products and technology and have links with large pharmaceutical
companies.



•  The Company's Chairman is Dr Gwyn Humphreys, a founder and chief
executive of Bradford Particle Design Limited, one of the UK's most successful
spin-out companies sold for $200 million in January 2001 to Inhale Therapeutic
Systems Inc. Syntopix' Chief Executive Officer is Rod Adams, who has extensive
experience in running and building healthcare companies, particularly in the
field of dermatology.



•  The Company believes that the market for dermatological products,
which has global annual sales of more than $10 billion and clear evidence of
unmet medical need, has suffered a lack of product innovation and there are many
limitations identified in some of the leading products. Syntopix' strategy seeks
to reduce the cost and risk of successfully discovering and developing
dermatology drugs by concentrating on change of use and combinations of known
compounds.



Commenting on the flotation, Rod Adams, Syntopix' Chief Executive Officer, said:
'I am delighted by the response to the Syntopix flotation.  Commencing life as a
public company is extremely exciting for us and we look forward to progressing
our drug development programmes in dermatology and to generating value for our
shareholders.'



                                          PLACING STATISTICS

Placing Price                                                                      177 pence

Number of Placing Shares                                                           2,259,887

Number of Non EIS Shares and Non VCT Shares                                        1,785,307

Number of EIS Shares and VCT Shares*                                               474,580

Number of Ordinary Shares in issue on Admission                                    5,683,981

Market capitalisation of the Company at the Placing Price on Admission             £10.1 million

Placing Shares as a percentage of the Enlarged Issued Share Capital                39.8 per cent.

Gross proceeds of the Placing receivable by the Company                            £4.0 million

Net proceeds of the Placing receivable by the Company                              £3.3 million



*Application has been made for admission of 474,580 Ordinary Shares in respect
 of the EIS Shares and the VCT Shares. Dealings are expected to commence in 
 these Ordinary Shares on 24 March 2006.


For further information please contact:


Syntopix Group plc                                              0845 1259204

Gwyn Humphreys, Chairman

Rod Adams, Chief Executive Officer

www.syntopix.com

KBC Peel Hunt Ltd                                               020 7418 8900

Megan MacIntyre

Buchanan Communications                                         020 7466 5000

Mark Court, Tim Anderson, Mary-Jane Johnson


Notes to editors



About Syntopix Group plc


Syntopix, a company focussed on the discovery and development of drugs for the
topical treatment of dermatological diseases, was founded in 2003 as a spin-out
from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the leading
experts in skin microbiology, with initial funding from The Wellcome Trust.


Syntopix' strategy is to seek to reduce the risks and costs of drug discovery
and development by discovering novel uses for known compounds; by concentrating
on compounds and combinations of compounds that have a history of safe use; and
working with compounds that have known properties, for example antimicrobials
and anti-inflammatories. The Company currently has seven pending UK patent
applications.


Syntopix is currently focussed on acne and Staphylococcus aureus infections and
has identified a pipeline of lead drug candidates that it intends to take
through pre-clinical and, as appropriate, clinical trials. The Company intends
to out-license products to commercial partners on obtaining proof of principle
and to seek co-development partnerships.


The Company is based at the Institute of Pharmaceutical Innovation in Bradford,
giving access to the expertise in skin biology, formulation and toxicology at
the universities of Bradford and Leeds.


Syntopix' shareholders include Techtran Group Limited, a subsidiary of IP2IPO
Group plc, The Wellcome Trust Limited, University of Leeds Limited, White Rose
Technology Ltd and Ridings Early Growth Investment Company Limited.


For further information please visit www.syntopix.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange     
MSCEAPDDAESKEEE